Aims Self-monitoring of blood or urine glucose is widely used by subjects with Type 2 diabetes mellitus. This study evaluated the effectiveness of the technique at improving blood glucose control through a systematic review and meta-analysis.
Introduction
In the UK Prospective Diabetes Study (UKPDS) in Type 2 diabetes mellitus, a long-term mean difference in glycated haemoglobin (HbA 1c ) between groups of 7.0 compared with 7.9%, was associated with a relative risk reduction of 25% (95% con®dence interval 7±40%) for the aggregate endpoint`microvascular complications' [1] . This observation has given added impetus to attempts to improve blood glucose control in people with Type 2 diabetes. Selfmonitoring is used extensively in Type 2 diabetes but there is uncertainty concerning its effectiveness at improving blood glucose control [2±4] . A systematic review and metaanalysis were carried out to estimate the size of effect of self-monitoring on glycated haemoglobin in Type 2 diabetes.
Methods
The review was restricted to studies that investigated the effectiveness of blood or urine glucose self-monitoring at improving blood glucose control in subjects with Type 2 diabetes. The search included the authors' personal reference collections; searches of Medline, Embase, IBSS (Index of Bibliography of Social Science) and the Cochrane Library; as well as hand searches of Diabetes Care, Diabetic Medicine and Diabetologia for the years 1990±1999. The search strategy included a series of keywords including`diabetes mellitus' and self-monitoring of blood glucose' combined with a search for randomized controlled trials. Citations of retrieved references were also screened. Letters were sent to the two leading manufacturers (Bayer and Roche Diagnostics) and the British Diabetic Association (UK Diabetes) to request information, but these enquiries did not yield any additional material. No attempt was made to review non-English language publications and authors of the studies reviewed were not contacted. Two of the authors independently rated papers for quality using a checklist designed for randomized and non-randomized studies [5] . This was used so that non-randomized studies could be appraised in the same way as randomized controlled trials. The checklist included subscales to rate the quality of reporting, external validity, and internal validity (bias and confounding). The checklist was modi®ed by adding an item concerning whether a full range of outcome measures was reported. Assessment of external validity was found to be unreliable, but it was nevertheless thought important to appraise this aspect of the studies. The statistical power of the studies was considered separately by estimating whether the study had suf®cient power to detect differences in GHb of`3%,`2%,`1%,`0.5% or`0.25%. The outcome data abstracted from the papers were checked thoroughly.
Meta-analyses were performed using the`meta' command [6] in the statistical package Stata [7] . In both of the meta-analyses, ®xed and random effects analyses gave identical results and a test for heterogeneity was negative [6, 8] . For each trial, the most reliable estimate of the treatment differences for which a standard error could be estimated based on the published data was used [9] . Thus, if data were reported for the change from baseline with standard errors then these were used, otherwise the difference between post-intervention values was used. As this approach only allowed for the analysis of differences between post-treatment values for some trials, we carried out a sensitivity analysis. Analyses were repeated using estimates for the change in GHb between the start and the end of the study. The standard error for the change was estimated by assuming a correlation between pre and post-intervention GHb values of 0.7. Meta-analysis results were plotted as a graph in which the point estimate for each study was plotted using a box whose area was inversely related to the variance of the estimate in that study [6] . Thus the area of the box was dependent, not just on the number of subjects, but also the design of the study and the data provided in the published report. Publication bias was evaluated using funnel plots and associated tests using the`metabias' command in Stata [10] .
Results
The initial search identi®ed 18 studies, of which 10 were excluded because they were non-randomized (Fig. 1) . The main design features of the eight controlled trials [11±18] are shown in Table 1 . The study by Rutten et al. [17] used cluster randomization. The study by Miles et al. [15] changed patient allocation on a weekly basis and was not truly randomized. The study by Allen et al. [11] reported that`patients were randomized in groups of 10 to a urine testing group or a self-monitoring blood glucose group with the use of a computer-generated table of random numbers'. Thus the mode of allocation was not entirely clear. The remaining ®ve studies used individual randomization. The criteria used to select subjects for the studies Potentially relevant studies identified and screened for retrieval (n=18)
Non-randomized studies excluded (n=10)
Potentially appropriate RCTs to be included in the meta-analysis (n=8)
RCTs retrieved for more detailed evaluation (n=8)
RCTs excluded, with reasons (n=0)
RCTs included in meta-analysis (n=6)
RCTs with useable information (n=6) blood or urine v no testing (n=4) blood v urine (n=3) (Note: includes one three-armed trial)
RCTs withdrawn (n=0)
RCTs excluded (n=2), one used fructosamine as outcome, one cluster randomised varied with respect to age distribution, duration of diabetes, quality of blood glucose control, and previous experience of monitoring. One study included subjects taking insulin [18] but the remaining studies included subjects treated with diet or oral hypoglycaemic drugs. A range of different methods were used to estimate glycated haemoglobin as outcome. Studies also varied with respect to the recommended frequency of self-monitoring, the advice given on modi®cation of therapy, the methods used to assess reliability and adherence with monitoring, and the duration of study. Loss to follow-up was substantial in some trials (Table 1) . Quality ratings were generally low (Table 2 ). It was estimated that three studies had suf®cient statistical power to detect differences in glycated haemoglobin (GHb) of between 0.5 and 1% but four studies only had suf®cient power to detect differences of more than 1%. Further details of the literature searches, excluded studies, critical appraisals, quality ratings (including assessments of reliability) and power calculations may be obtained from our full project report [19] .
One study was not included in the meta-analysis because fructosamine was used as the outcome measure [14] . One study was excluded because it was a cluster randomized study of a complex intervention [17] . One of the studies included in the meta-analysis was a three-armed trial which compared groups using either blood testing, urine testing or no testing [13] . The data abstracted from the studies for the meta-analysis are shown in Table 2 . A meta-analysis was performed using data from four studies which compared patients who monitored blood or urine glucose with patients who did not monitor regularly. This analysis included data for 285 subjects. The estimated reduction in GHb from monitoring was ±0.25% (95% con®dence interval ±0.61 to 0.10%) (Fig. 2) . This result indicated a small reduction in GHb from monitoring which was not signi®cantly different from zero. Three studies which compared GHb in patients who monitored blood glucose with those monitoring urine glucose were also combined. For the cross-over study by Miles et al. [15] , a comparison of subjects who used blood monitoring initially was made with those who used urine monitoring ®rst. The analysis included 278 subjects. The estimated reduction in GHb from monitoring blood glucose rather than urine glucose was ±0.03% (±0.52 to 0.47%). This difference was not statistically signi®cant. Tests for heterogeneity were not signi®cant for either meta-analysis. There was no evidence for publication bias in either of the analyses presented.
The results of the sensitivity analyses gave estimated intervention effects of ±0.138% (±0.597 to 0.318%) for blood or urine monitoring compared with no monitoring, and ±0.024% (±0.505 to 0.458%) for blood monitoring compared with urine monitoring.
Analyses were also repeated after excluding the trial by Estey et al. [12] because the intervention in this trial was complex. This analysis gave an estimated difference in GHb between groups performing any monitoring and no monitoring of 0.010% (±0.578 to 0.598%). The analysis was also repeated after excluding the study by Miles et al. [15] because it was not fully randomized. This gave a difference in GHb between blood and urine monitoring groups of ±0.182% (±0.915 to 0.552%). These sensitivity analyses provided evidence that the results presented were not particularly sensitive to the approach used for metaanalysis.
Discussion
Self-monitoring of blood or urine glucose is often advocated as a means to improve blood glucose control, and the technique was an integral part of the management strategy for the Diabetes Control and Complications Trial in Type 1 diabetes [20] . In the UKPDS [1], advice on monitoring varied according to the quality of blood glucose control and the trial results did not help to clarify whether self-monitoring was of bene®t (R Turner, personal communication).
This meta-analysis did not provide evidence of bene®t from self-monitoring. The results were imprecise and neither an appreciable bene®cial effect nor a small adverse effect could be excluded. The con®dence intervals associated with the estimate of GHb reduction were wide and it is possible that self-monitoring of blood or urine glucose might be associated with a reduction in GHb of up to 0.6%. In the UKPDS, a difference between groups of 7.0% compared with 7.9% was of clinical bene®t over 10 years [1] . Over the study cohort, a 1% reduction in average HbA 1c was associated with a 21% (17±24%) lower risk of any diabetes-related endpoint [21] . Analyses of data from the Diabetes Control and Complications Trial in Type 1 diabetes also suggested that small differences in HbA 1c would be clinically important [22] . There was no evidence from this review to show that blood glucose monitoring was superior to urine glucose monitoring in terms of improved blood glucose control. The individual studies did not provide clear evidence of other bene®ts such as the avoidance of hypoglycaemia or improvements in healthrelated quality of life.
The meta-analysis inevitably re¯ected the limitations of the studies which it included. The studies included were generally poorly reported and lacking in statistical power. Several of the trials were of short duration and this may not have permitted a full assessment of the effects of selfmonitoring. It might also be argued that it is undesirable to combine results obtained using different methods for glycated haemoglobin estimation. It is well known that systematic reviews of the same topic may give differing results [23] , it was therefore reassuring that a number of sensitivity analyses con®rmed the essential ®ndings of the main analyses. Two other recent reviews of self-monitoring [12] validity [3] ± bias [7] ± confounding [6] in GHb (%) Main ®ndings (Mean (SD) except where indicated)
Allen [11] pre', before intervention; ¢post', after intervention; ¢diff', difference between before and after. GHb, glycosylated haemoglobin.
in Type 2 diabetes also reached similar conclusions to the present review [3, 4] , although neither included a metaanalysis. Diabetes care is a complex intervention made up of a number of different components of treatment, care and education. Mulrow and Pugh [24] observed that for complex interventions`although treatments aimed at certain facets may be more ef®cacious than others, we cannot expect interventions aimed at single parts of a complicated treatment to be highly ef®cacious' [24] . In the present context, the use of self-monitoring may be highly dependent on the type and quality of diabetes education which patients receive. In the trials included in this review, there was an obvious lack of standardization of training and advice on use of self-monitoring. In a study in Type 1 diabetes, Worth et al. [25] showed that patients taking part in an intensive, 6-month education programme with urine glucose monitoring, showed an improvement in blood glucose control. During a subsequent 9 month evaluation of blood glucose monitoring, there was no further improvement in control. The authors suggested that the main bene®t of self-monitoring was as an educational modality, leading to increased contact time with diabetes care staff and greater motivation. Any effects were, they suggested, short-lived and they suggested that future research should focus on long-term results.
Several studies noted that blood glucose self-monitoring was more costly than urine glucose self-monitoring, which in turn was more costly than no self-monitoring. In the absence of evidence for clinical effectiveness of blood glucose self-monitoring, there seems little justi®cation for encouraging Type 2 diabetic patients to purchase costly testing equipment. This is particularly relevant in countries with fewer resources. Healthcare costs include not just the costs of equipment and supplies, but also the staff time used in busy clinics to teach patients to test, and to review their results. In terms of opportunity cost, more time spent teaching self-monitoring may result in less attention being given to other aspects of self-management such as foot care. Further work to clarify the use of self-monitoring in Type 2 diabetes appears to be needed so that resources for diabetes care can be used more ef®ciently. In agreement with the recommendation by Faas et al.
[3], a large randomized trial of the effect of blood glucose selfmonitoring in Type 2 diabetes is desirable. It would also be feasible to conduct trials of discontinuation of selfmonitoring in subjects with stable Type 2 diabetes. Finally, where good quality clinical data are available it may be possible to carry out observational analyses to attempt to identify groups of patients in whom self-monitoring may be unnecessary [26] . Urine or blood monitoring compared with no monitoring
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